From Jerry's Site

[Guest guest]

VX-680 and the T315I mutation.

by Jerry Mayfield

A good friend of mine who sees Dr. Giles at M. D. sent me this

and asked me to post it. It is very good news for those with T315I.

Jerry

***********************************************

Hi all. I had a good visit with Dr. Giles and Alma on Tuesday this

week at M.D. Dr. Giles has asked me to share some very

important updated to the Global CML Community. I took notes fast and

furiously so I can barely read my own handwriting so I hope I am sharing

what he told me verbatim.

Trials are starting for the MK0457 drug (VX680). This drug is the only

one at this point that is showing good results against the dreaded T3151

mutation. It looks VERY PROMISING per Dr. G. The drug is a bit unique -

in that it is given intravenously at this time. The first patient was

started on the drug in November of 2005. While it might take a few

courses of the drug, they are seeing the T3151 mutation disappear. Dr.

Giles said there is no doubt that there is strong clinical activity

regarding this new compound.

Trials will be starting in a few months. He wants to the CML Community

to know that if you have failed the BMS and AMN trials, you may be

eligible. You can contact Dr. Giles via Alma Welch - at

mawelch@.... Alma is his Physician's Assistant who can

share additional information with you.

If I am understanding this correctly, the VX drug works on the JAK2 -

and it appears there are indications that it can also treat

myeloproliferative disease. Merck has found this new drug so promising

that they have halted some other main line drug studies to get this

compound to the forefront. That's a very good message from Merck that

they are really looking at CML treatment which certainly isn't as common

as other cancers like solid tumors. Hats off to Merck!

" Coming to a Medical Center near You " . . . if you are interested in

this VX study, they are looking for patients. The following centers will

be opening trials shortly:

M.D. Cancer Center - Houston - Dr. Francis Giles

Duke University - Durham, NC - Dr. Dave Rizeri

furt, Germany - Dr. Ottman (I believe he is a collegue of Dr.

Hochhaus)

Hammersmith - London, UK - Dr. Jane Apperly

I hope I translated Dr. Gile's important message with as much accuracy

as possible. This is exciting news for the CML community that there is

an agent that looks VERY promising against this T315 mutation. Again,

please feel free to contact Dr. Giles or one of the other doctors I've

listed.

Hope this finds everyone doing well.

Barb Heathcote